Synopsys, Inc. (SNPS) Market Cap & Valuation Ratios
Synopsys, Inc. (SNPS) has a market cap of $82.4B, a trailing P/E of 76.9 and a price-to-sales ratio of 8.8, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason
SNPSSynopsys, Inc.Follow SNPS — free
—
Price chart with a free account
- Market cap
- 82.4B
- P/E TTM
- 76.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 8 Dec, in 45 days
Peers
software - infrastructure · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| SNPS | 82 | 76.9 | 9.4 | 34.0 | 3.3% | +46% | 9% | 2% |
| FTNT | 132 | 63.6 | 17.1 | 49.4 | 2.3% | +19% | 32% | — |
| NET | 116 | — | 45.8 | — | 0.3% | +34% | -14% | -11% |
| XYZ | 46 | 136.5 | 1.9 | 30.0 | 8.5% | +5% | 5% | 3% |
| NTAP | 42 | 30.4 | 5.6 | 20.3 | 3.9% | +12% | 25% | 76% |
| TWLO | 40 | — | 6.9 | 85.7 | 2.5% | +18% | 5% | 2% |
| ZS | 40 | — | 12.2 | 2674.8 | 1.9% | +25% | -4% | -6% |
| OKTA | 37 | 128.3 | 11.4 | 110.2 | 2.6% | +11% | 8% | 3% |
| CRWV | 30 | — | 7.8 | 15.8 | — | +115% | -3% | -0.7% |
| MDB | 30 | — | 9.9 | 2224.6 | 2.2% | +25% | -0.5% | -0.7% |
| VRSN | 27 | 32.3 | 16.3 | 23.6 | 3.8% | +6% | 68% | — |
| Median of these 10 | 63.6 | 10.6 | 49.4 | 2.5% | +18% | 5% | 0.7% |
P/E 76.9 vs. a peer median of 63.6; EV/Sales 9.4 vs. 10.6. SNPS's own P/E sits at the 92nd percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesNET and TWLO and ZS and CRWV and MDB have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Synopsys, Inc. — questions
- What is Synopsys, Inc.'s market cap?
- $82.4B.
- What is Synopsys, Inc.'s P/E ratio?
- 76.9 on trailing twelve-month earnings to 2026-07-31.
- What is Synopsys, Inc.'s price-to-sales ratio?
- 8.8.
Every figure on this page comes from Synopsys, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.